A gene therapy subject in an early human trial to treat arthritis has died, causing the experiment to be halted. Very sad. But such are the risks in human trials, which sometimes puts people in potential peril in the effort to get cutting edge medical treatments to clinical use. (There are, of course, cases in which known risks are not disclosed, as in the 1999 gene therapy death of Jesse Gelsinger, which is not part of the usual process.)
There has been so much hope placed in this biotechnological approach, but this isn’t the first such death, and it may indicate that it will be a very long time before this potentially promising treatment modality is available—if ever.
This event should remind us that biotechnology seeks to harness the power of sheer biology. That can be risky, which is why people should be wary. We must take this one step at a time.
You have a decision to make: double or nothing.
For this week only, a generous supporter has offered to fully match all new and increased donations to First Things up to $60,000.
In other words, your gift of $50 unlocks $100 for First Things, your gift of $100 unlocks $200, and so on, up to a total of $120,000. But if you don’t give, nothing.
So what will it be, dear reader: double, or nothing?
Make your year-end gift go twice as far for First Things by giving now.
